U.S. market Closed. Opens in 7 hours 42 minutes

DTIL | Precision BioSciences, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 8.02 - 8.95
52 Week Range 7.97 - 19.43
Beta 1.46
Implied Volatility 421.86%
IV Rank 100.00%
Day's Volume 131,865
Average Volume 59,353
Shares Outstanding 7,233,760
Market Cap 59,967,870
Sector Healthcare
Industry Biotechnology
IPO Date 2019-03-28
Valuation
Profitability
Growth
Health
P/E Ratio 31.88
Forward P/E Ratio N/A
EPS 0.26
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 110
Country USA
Website DTIL
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
*Chart delayed
Analyzing fundamentals for DTIL we got that it has average fundamentals where Valuation is considered to be fairly valued, Profitability is stunning wealthy, Growth is bad and Health is very weak. For more detailed analysis please see DTIL Fundamentals page.

Watching at DTIL technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on DTIL Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙